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ABSTRACT 
BACKGROUND: The protein tyrosine phosphatase non receptor type 22 (PTPN22) gene 
inhibits T-cell activation. A functional single nucleotide polymorphism (SNP) Arg620Trp 
(rs2476601), resulting from a C→T substitution at nucleotide position 1858, is a 
significant risk factor for rheumatoid arthritis (RA) in European populations. The variant 
allele results in a gain of function that alters the threshold for T-cell signalling and 
abnormal T regulatory cell function. 
AIM: To investigate the role of the PTPN22 R620W polymorphism in disease 
susceptibility and severity in Black South Africans (BSA) with RA. 
METHODS: A cohort of 187 BSA patients with RA and 93 ethnically matched Black and 
60 White controls with no history of RA or other autoimmune diseases were studied. 
Genotyping was performed by the polymerase chain reaction and pyrosequencing.  
RESULTS: The rs2476601 SNP was nonpolymorphic in both Black patients and Black 
control subjects with total absence of the variant ‘T’ allele. In White control subjects the 
frequency of the ‘T’ allele was 0.092, with T/T, C/T and C/C genotype frequencies of 0.00, 
0.183, and 0.817, respectively.    
CONCLUSION: This study shows that the rs2476601 SNP of the PTPN22 gene is 
nonpolymorphic in BSA and therefore not associated with RA but the minor ‘T’ allele 
frequency in White South Africans is similar to that in other European populations. 
However, since variations in the rest of the gene were not investigated, these results do not 
exclude other PTPN22 polymorphisms from playing a role in RA susceptibility in BSA.  
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Chapter 1.  INTRODUCTION AND LITERATURE REVIEW 
1.1 History of rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis of unknown aetiology. The 
history of RA is unclear. There is a suggestion that this disease dates back to the 1500s. 
Historical characters such as Erasmus, considered as the ‘Prince of Humanism’, Louis 
XIV, Kant and others had suffered some form of arthritis. The paintings of Rubens, Renoir, 
Klee and Dufy depict physical changes which many physicians have described as being 
consistent with ‘modern day’ RA (Dieppe and Rogers, 1986). 
The first recognized description of RA was made in 1800 by the French physician, Dr 
Augustin Jacob Landre-Beauvais who was based in the famed Salpetriere Hospital in Paris. 
The name ‘rheumatoid arthritis’ itself was coined in 1859 by a British rheumatologist, Dr 
Alfred Baring Garrod (Keitel, 2009).  
1.2 Epidemiology and clinical features 
RA is the most common autoimmune disease, afflicting 0.5-1% of adults worldwide. RA 
affects twice as many females than males. The peak age of onset is the 4
th
-5
th
 decade of 
life. The prevalence increases after the age of 60 years. The peak age of incidence is 
between the 4
th
 and 6
th
 decade of life (Gabriel et al., 1999).  
Epidemiological studies done in black South Africans (BSA) in the 1970s showed that the 
prevalence of confirmed RA was 0.12% in the rural Tswana (Beighton et al., 1975). This is 
in contrast to the prevalence of 1% documented in Caucasians. Furthermore, the severity of 
RA is thought to be less in Africans (Adebajo and Reid, 1991,Chikanza et al., 1994). 
However, a study done in urban blacks of Soweto showed that the prevalence was 
estimated to be 0.9-1.4% and urban dwellers had more severe disease and resembled 
features of the classical RA observed in the Caucasian population (Solomon et al., 1975). 
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More recent studies done in Johannesburg show that the disease is frequently severe and 
can be associated with severe disability (Tikly et al., 2003,Solomon et al., 2005).  
RA is characterised by persistent synovitis usually involving peripheral joints in a 
symmetrical distribution. RA can potentially affect any synovial joint. Classical RA causes 
swelling of the small joints of the hand as depicted in Figure 1.1.  
 
Figure 1.1 Hand involvement with swelling of the proximal interphalangeal joints in RA  
However, an African variant has been described which affects predominately the wrists 
and spares the small joints of the hands (Maritz et al., 2003). 
Inflammation of the organs may occur, predominately in rheumatoid factor (RF) positive 
patients. Rheumatoid nodules are a common manifestation of RA. Other extra articular 
features include rheumatoid lung (interstitial lung disease and bronchiolitis), 
keratoconjunctivitis sicca, scleritis, serositis, anaemia of chronic diseases and vasculitis. 
Risk factors for severe RA include RF and anti- citrullinated protein antibody (ACPA) 
positivity (Niewold et al., 2007), genetic susceptibility, smoking (Baka et al., 2009, 
Nyhall-Wahlin et al., 2009). Poor prognostic features of RA are poor functional class at 
presentation, poor socioeconomic background, older age at presentation, erosive disease 
and the presence of extra- articular disease.  
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1.3 Health and economic burden  
Cost-of-illness studies have shown that RA is associated with a high health and economic 
burden (Boonen and Mau, 2009). The economic ‘burden’ of disease relates to both direct 
and indirect costs. 
The direct cost relates to the actual payment made for diagnosis, therapy, complications 
and prevention of the disease. The direct costs of RA are 2-3 times higher than the average 
cost for individuals of a similar age and gender (Lubeck, 2001). 
The indirect costs of RA are substantial and relate to loss of resources to the individual, 
their family and society. These costs relate to work disability and early retirement. 
Approximately a quarter of patients will discontinue paid work within 2 years of RA 
diagnosis (Kvien, 2004). A South African study showed that only 24% of RA patients were 
employed and 35% were dependent on financial support from the state (Mody et al., 1988). 
Indirect cost of RA is also linked to an increased mortality due to RA. Life expectancy is 
decreased by 5-10 years. The five-year survival of patients in the American College of 
Rheumatology (ACR) functional class four is similar to those patients of triple vessel 
disease or stage IV Hodgkin’s lymphoma (Pincus et al., 1984). The major causes for death 
in RA are cardiovascular and cerebrovascular disease (Douglas et al., 2006, Meune et al., 
2009).  
The psychosocial burden of the disease includes loss of quality of life, pain, frustration and 
lack of self esteem. Studies done in South Africa showed that RA has a significant effect 
on health-related quality of life (Benitha and Tikly, 2007) and it is also associated with a 
negative impact on the individual’s  psychological and social functioning (Schneider et al., 
2008).  
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1.4 Pathogenesis 
During normal embryonic development, the immune system is tolerized to self antigen. T-
cells in the thymus undergo positive and negative selection to only recognize non-self 
antigen in the context of major histocompatibility complex (MHC) molecules. 
Autoreactive T-cells that escape this process are controlled by peripheral regulatory T cells 
(Tregs). The early breach in T-cell and B-cell tolerance that occurs in RA is poorly 
understood. It is probable that there is both aberrant thymic selection and peripheral 
tolerance. Naturally occurring Tregs seem to have impaired regulatory function (McInnes 
and Schett, 2007).  
The T-cell phenotype in RA has been thought to be T helper 1(TH1) cell type however 
recent animal studies implicate TH17 as the key effector cell subtype (Cooles and Isaacs, 
2011). TH17 cell production can be induced by interleukin (IL)-6, transforming growth 
factor beta (TGFβ) and IL-23. Synovial T cells contribute to synovitis through enhancing 
T-cell activation, endothelial permeability, plasma cell hyperactivity, macrophage/antigen 
presenting cell activation, and through the production of inflammatory cytokines such as 
IL-1, IL-6, IL-8, IL-10, tumour necrosis factor (TNF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Pratt et al., 2009). Angiogenesis, the formation of high 
endothelial venules and the expression of endothelial adhesion molecules promote 
migration of T-cells into synovial tissue. 
The role of B cells in the pathogenesis of RA is through the production of autoimmune 
antibodies, cytokines and chemokines such as IL-6, IL-10 and LTβ production and the 
ability to present antigen. Plasma cells secrete immunoglobulins e.g. RF and ACPA. 
Various RF isotypes form immune complexes which are capable of complement fixation 
and neutrophil activation. 
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Macrophages are key to the production of inflammatory cytokines. They are activated 
through pattern-recognition receptors. Macrophages produce cytokines, of which TNF is of 
primary importance. TNF induces leukocyte, endothelial cell activation and synovial 
fibroblast activation. TNF also induces angiogenesis and cytokine production such as IL-6, 
IL-15, and IL-1.  
Osteoclast differentiation is achieved by the actions of TNF and IL-1, as well as of IL-17, 
produced by TH17 cells, and IL-7, produced by synovial fibroblasts. By contrast, IL-4 and 
IL-10, which are produced by TH2 cells, and GM-CSF and interferon-  (IFN ), which are 
produced by TH1 cells, inhibit osteoclast differentiation.  
Cartilage degradation is a multistep process based on the release of matrix-degrading 
enzymes such as aggrecanases (ADAMTS) and matrix metalloproteinases. Cytokines such 
as IL-1 and IL-17 induce a switch in the synthesis pattern of chondrocytes from matrix 
molecules to matrix-degrading enzymes. In addition, synovial fibroblasts produce matrix-
degrading enzymes and invade cartilage when activated by cytokines such as TNF and IL-
1. Chondrocyte death is another feature of cartilage damage, it leads to the formation of 
empty lacunae and deprives cartilage from the ability to replenish matrix. 
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Figure 1.2 Pathogenesis of RA (McInnes and Schett, 2007) 
1.5 Aetiology  
The aetiology of RA remains unknown. RA is thought to occur in a genetically susceptible 
host that is then exposed to infectious, environmental, hormonal or other yet unidentified 
triggers. 
Infections such as Epstein-Barr virus (Ollier, 2000, Saal et al., 1999), Parvovirus B19 and 
mycobacteria probably cause disease through molecular mimicry of specific microbial 
peptides with autologous molecules such as the rheumatoid or cartilage-derived epitopes. 
However, convincing evidence of a specific pathogen-derived antigen or of cross-reactivity 
of self-antigen-specific T or B cells with pathogen derived peptides is lacking. 
Smoking confers not only an increased risk of developing RA, but also influences the 
course of the disease. Smoking is the most prominent example of a gene-environment 
interaction in RA pathogenesis. A meta-analysis revealed that smoking is a risk factor for 
RA, especially RF+ males and heavy smokers (Sugiyama et al., 2010).  Tobacco exposure 
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increases the risk for ACPA+ RA, but only in shared epitope positive patients (Linn-
Rasker et al., 2006). 
RA occurs more frequently in women than men. Oestrogen exerts a stimulatory effect on 
the immune system by inhibiting T cell suppressor function and facilitating T cell 
maturation (Cutolo, 2004). Women with older age at menarche (>15) have an almost 2-
fold increased risk of developing RA as compared to women with early menarche (<12). 
Pregnancy increases the risk of developing RA. Twelve percent of women with RA 
develop RA within a year after pregnancy. Females having multiple pregnancies are at risk 
of severe RA. Longer duration of breastfeeding increases the risk of RA in individuals who 
are ACPA positive in the presence of the PTPN22 risk allele (Berglin et al., 2010). The use 
of the oral contraceptive pill delays onset of disease rather than protect against its 
occurrence (Doran et al., 2004). 
Occupational exposure to mineral oils was found to be of an increased risk of RA in a 
Swedish study (Sverdrup et al., 2005). A diet low in antioxidants, e.g. vitamin C and β-
cryptoxanthin, has been found to increase the  risk of RA, as has excessive coffee 
consumption, however only in ACPA + RA (Pattison et al., 2005).  
1.6 The Genetics of RA 
The evidence for a significant genetic component to RA susceptibility was shown by the 
excess disease concordance in monozygotic twins (15%) compared to dizygotic twins   
(3.6%) (MacGregor et al., 2000). The increased risk of the disease in siblings of patients 
with RA compared with that of the general population has been estimated to be between 2 
and 17 fold. 
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1.6.1 The HLA genes and RA 
It is estimated that the heritability for RA is 50-60% (MacGregor et al., 2000),  
 a third of which is accounted for by polymorphisms of the HLA-DRB1 gene. The strongest 
link between genetic susceptibility and RA is the association of the disease with an epitope 
in the third hypervariable region of β-chain of the HLA-DR molecule, also known as the 
‘shared epitope’ (SE) (Gregersen et al., 1987). SE alleles are found in ~60-70% of 
European ancestry subjects with RA, compared to ~40% of controls. The DRB1*0401 
allele confers a relative risk (RR) of 5 for RA, more than any other single gene or allele so 
far identified. Studies in BSA with RA showed a strong association with HLA-DR4 
haplotypes, DR1 and DR4 (Martell et al., 1989, Mody et al., 1989, Pile et al., 1992). 
Furthermore, certain alleles, HLA-DRB1*0401 and *0404, were associated with severe 
erosive disease (Meyers et al., 2004). It is thought that additional risk alleles within the 
major histocompatibility complex (MHC) exist, but these alleles remain to be pinpointed 
precisely. The SE still remains the only genetic risk that confers susceptibility for RA 
across all ethnic groups. Non HLA susceptibility genes, however have failed to show 
consistency between different populations.  
1.6.2 Non HLA genes and RA 
In total, the HLA genes only contribute 30-50% of the genetic variability of RA. In the 
European population, the second strongest genetic risk outside of the HLA region is a 
functional single nucleotide polymorphism (SNP) in the PTPN22 gene which is a C→T 
substitution at nucleotide position 1858 (rs2476601), which results in a substitution of 
trytophan (W) for arginine (R) at codon 620 (Begovich et al., 2004). In European 
populations T allele carrier rate in RA patients is 1.38-2.04 fold compared to the general 
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populations. However, the rs2476601 SNP was not found to be associated with RA in the 
Asian population (Lee et al., 2009, Ikari et al., 2006).  
Ethnic differences in genetic susceptibility in RA between European and Asian populations 
are evident with the PADI4 gene. Polymorphisms in the PADI4 gene are associated with 
the second strongest genetic risk outside of the HLA region in Asians (Iwamoto et al., 
2006). This association has not been found in the European populations (Burr et al., 2010) . 
Lee et al studied genetic variants at 4q27, 6q23, CCL21, TRAF1/C5, and CD40 in 
Koreans. None of the susceptibility loci identified in Caucasian patients with RA 
contributed significantly to disease in Koreans (Lee et al., 2009). 
In patients of African ancestry ethnic differences are evident in differential susceptibility of 
the interleukin 10 (IL10) (MacKay et al., 2003) and the corticotrophin releasing hormone 
(CRH) gene (Baerwald et al., 2000) compared to Caucasians. STAT4 variants have been 
associated with RA in Asians and Europeans populations but not in African Americans 
(Kelley et al., 2010). The association was previously confirmed in two other studies in 
Asians (Lee et al., 2007, Kobayashi et al., 2008) 
Although there is much emerging data, the genome wide association studies (GWAS) have 
been done primarily in European-Caucasian patients and there is limited data relating to 
susceptibility and severity gene variants in patients of African descent. 
1.6.3 Genetic variants associated with RA severity 
Genes associated with severity of disease have mostly been studied in Caucasian 
populations. Apart from the HLA SE alleles, only 6 other loci have been associated with 
RA radiographic severity: CD40 (rs4810485), KIF5A/PIP4K2C (rs1678542), CDK6 
(rs42041), CCL21 (rs2812378), PRKCQ (rs4750316), PTPN22 (rs2476601) and 
MMEL/TNFRSF14 (rs3890745) (van der Linden et al., 2009, Orozco et al., 2010., Marinou 
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et al., 2010, Steer et al., 2005). There is a paucity of information relating to the genetic risk 
loci associated with severe RA in African patients. This is in part, due to the lack of 
identified susceptibility genes and of appropriate clinical, serological and radiological 
databases. 
1.6.4 Genome wide association studies (GWAS) and candidate gene analysis 
Most genetic studies in RA have been single candidate gene studies.  They involve 
investigating genes that have known function or association with RA or other autoimmune 
disease. Candidate genes have usually been selected based on biological studies of disease 
pathogenesis.  
Advances in high throughput technology now allow identification of a large number SNPs 
simultaneously and have facilitated large case control collections or GWAS 
(Raychaudhuri, 2010). The GWAS approach is revolutionary because it permits 
interrogation of SNPs throughout the entire human genome in thousands of unrelated 
individuals without any prior hypotheses regarding genetic association with diseases.  
There are limitations to both the GWAS and candidate gene approaches. In GWAS, 
because of the massive number of statistical tests performed there is potential for high rates 
of false positive results. There is also lack of information on gene function, insensitivity to 
rare variants and structural variants, requirements for large sample sizes, and possible 
biases due to case and control selection and genotyping errors   (Newton-Cheh and 
Hirschhorn, 2005,Pearson and Manolio, 2008). 
.There is often limited information available about environmental exposure and other non-
genetic risk factors in GWA studies. This makes it difficult to identify gene-environment 
interactions or modification of gene-disease association in the presence of environmental 
factors. 
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GWAS has advantages over the candidate gene approach which uses costly genotyping 
methods. This limits the number of variants assayed to at most several hundreds. The 
candidate genes are selected based on an imperfect understanding of biological pathways. 
Many candidate gene studies have failed to replicate in subsequent studies. 
In the last few years genome-wide association studies and other large scale genetic studies 
have identified as many as 31 risk RA loci outside of the HLA region (figure 1.2) (de 
Vries, 2011). 
 
 
Figure 1.3 Odds ratio of the risk allele for RA (left axis and bars) and cumulative genetic 
variance explained by loci (right axis and line) (Raychaudhuri, 2010) 
1.6.5 The protein tyrosine phosphatase non receptor type 22 gene (PTPN22) 
1.6.5.1 The single nucleotide polymorphism (rs2476601) 
As mentioned earlier, a functional SNP R620W is the strongest genetic association outside 
of the HLA region in Caucasian populations. In 2004, a candidate gene approach study 
showed that the minor allele T confers a predisposition to type 1 diabetes in American and 
Italian populations (Bottini et al., 2004).  Begovich et al. reported the same association in 
RA using firstly a screening strategy of examining 16 000 potential functional SNPs in 
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genes that were candidates for RA or were located in linkage regions identified in RA 
whole-genome screening, followed by fine mapping  (Begovich et al., 2004). 
1.6.5.2 The role of the PTPN22 gene 
The PTPN22 gene maps to chromosome 1p13.3-p13.1. The gene encodes a lymphoid-
specific phosphatase (Lyp). Lyp is expressed in haemopoietic tissues, thymus, spleen and 
bone marrow as well as peripheral blood mononuclear cells. 
Lyp binds to C-terminal Src kinase (Csk), an intracellular tyrosine kinase, through a 
proline rich binding site, SH3 (Bowes and Barton, 2008). Tyrosine phosphatases (TP) 
function in a coordinated manner with protein tyrosine kinases in the regulation of 
signalling responses. Kinases are involved with controlling the amplitude of a signalling 
response and phosphatases are important for controlling the rate and duration of the 
response. The biological mechanisms underlying the association between PTPN22 and RA 
are incompletely understood. The polymorphism leads to a gain of function. Enzyme 
activation is thought to lead to an increase in the threshold for T-cell receptor signalling. 
   
Figure 1.4 PTPN22 polymorphism: The proposed mechanism of autoimmunity (Gregersen, 
2005)  
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Although the exact mechanism of autoimmunity is not known, it is thought to have effects 
on the thymus and T reg cells. In the thymus, this altered signalling could result in positive 
selection of thymocytes that would normally have been removed and this in turn leads to 
an increase in the number of autoreactive T cells in the periphery. A second mechanism of 
autoimmunity is altered signalling in Treg cells which lead to altered surveillance and an 
increase in autoregulatory T cells. 
1.6.5.3 PTPN22 polymorphism and ethnic populations 
The increase in T allele frequency in RA cases compared with controls has been replicated 
in numerous European populations (Seldin et al., 2005, Plenge et al., 2005, Pierer et al., 
2006). Although the PTPN22 has consistently shown to be associated with RA in 
Caucasians, the R620W risk allele in this gene is not found in Asian populations. The 
R620W SNP was nonpolymorphic in both Japanese (Ikari et al., 2006) and Korean (Lee et 
al., 2009) populations. This highlights that susceptibility genes associated with disease in 
Caucasians do not always play a role in other ethnic populations.  
1.6.5.4 PTPN22 polymorphism and autoimmunity 
Apart from the HLA region, one of the best examples of a genetic contribution to 
autoimmunity is the PTPN22 gene. Several studies have confirmed its association with 
type I diabetes (Smyth et al., 2004, Zheng and She, 2005), systemic lupus erythematosus 
(Orozco et al., 2005, Kyogoku et al., 2004), and Graves’ disease (Velaga et al., 2004, 
Skorka et al., 2005). 
1.6.5.5 The PTPN22 polymorphism and RA severity 
There is evidence that the PTPN22 polymorphism is associated with disease severity. In a 
British cohort disease occurred earlier and was associated with more erosive disease (Steer 
et al., 2005). However, other studies did not observe an association between the PTPN22 
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risk variant and radiological damage (Wesoly et al., 2005,Karlson et al., 2008).  In the 
presence of ACPA, disease occurred even earlier (Kokkonen et al., 2007). 
1.6.5.6 The PTPN22 polymorphism and predicting RA 
The PTPN22 R620W variant has been found to be a predictive marker for the development 
of RA. The combination of this variant and ACPA antibodies was found to have a 
specificity of 100% for diagnosing future onset RA (Johansson et al., 2006). In patients 
with undifferentiated arthritis the R620W did not predict RA development over the  
predictive value of ACPA alone (Feitsma et al., 2007). 
1.7 Aim of the study 
To investigate the role of the PTPN22 R620W polymorphism in disease susceptibility and 
severity in black South Africans with rheumatoid arthritis.
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Chapter 2.  PATIENTS AND METHODS 
2.1 Study population 
The study population comprised of a sample of 187 consecutive, unselected, unrelated, 
consenting BSA patients with RA attending the Arthritis Clinic of the Chris Hani 
Baragwanath Hospital. All patients with RA were older than 18 years of age at disease 
onset and met the American College of Rheumatology (ACR) 1987 revised criteria for the 
classification of RA (Arnett et al., 1988) (APPENDIX A). Assessment of severity was 
assessed by the presence of extra-articular manifestations, mean CRP at baseline, 
functional disability as measured by the modified health assessment questionnaire 
(mHAQ) (Pincus et al., 1983), (APPENDIX B), history of joint replacement and 
radiological assessment using the modified Larsens score (Wick et al., 2003). 
Radiographic damage is assessed by the modified Larsen method. The joints that are 
assessed include the 2 interphalangeal joints of the big toe, 10 metatarsophalangeal joints, 
4 quadrants of the 2 wrists, 2 interphalangeal joints of the thumb, 8 proximal 
interphalangeal joints and 10 metacarpophalangeal joints. The maximum possible Larsen 
damage score (LDS) is 200. 
The mHAQ comprises 8 domains relating to different aspects of daily activity. Each 
domain has questions that are scored out of 3, 0 equates to no assistance required while 3 
to almost complete dependence on others to perform daily activities. 
 They were compared to 93 geographically and ethnically matched Black controls and 60 
White controls for which no history of RA or other autoimmune diseases were noted in the 
self reported questionnaire at the time of enrolment. Patients and controls who were self 
confessed Africans were regarded as being Black if all four grandparents were of African 
descent. The Black controls were mainly staff members of the hospital or patients admitted 
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to casualty with minor injuries. The DNA samples of White controls were made available 
from the molecular genetics laboratory at the National Health Laboratory Service.  
Informed consent was obtained from every subject. This study was approved by the 
University of the Witwatersrand Human Research Ethics Committee (APPENDIX C). 
2.2 Laboratory investigations 
2.2.1 Serology 
Rheumatoid factor and anti-cyclic peptide antibodies (anti-CCP), a subgroup of ACPA 
were measured by the enzyme-linked immunosorbent assay. Individuals with RF > 
11IU/ml and anti-CCP> 10 IU/ml were regarded as positive.  
2.2.2 Genotyping 
2.2.2.1 DNA extraction 
The DNA was extracted using the salting-out method that was first described by (Miller et 
al., 1988). Patient’s blood was collected in EDTA tubes to prevent clotting and was stored 
at -20ºC until it was required for extraction. The blood was thawed prior to proceeding 
with DNA extraction and thereafter approximately 10ml of blood was transferred to 
NUNC tubes. The tube was filled with Sucrose-Triton X(S-T X) Lysing buffer, which 
lyses the blood cells. The tubes were inverted a few times to assist mixing.  The tubes were 
centrifuged for 10 minutes at 2300rpm, thereafter the supernatant was removed and a red 
pellet remained. The pellet was resuspended in S-T X lysing buffer and placed on ice for 5 
minutes. The mixture was then centrifuged again for 5 minutes at 2300rpm .The 
supernatant was again discarded and the pellet mixed with 1.5ml of T20E5 solution. 
Thereafter 100µl of 10% SDS and 250µl of Proteinase K was added to the solution.  The 
mixture was incubated for 24 hours, allowing the Proteinase K to digest the remaining 
protein. 
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After 24 hours 1ml of saturated NaCl solution was added. The mixture was vigorously 
shaken for 15 seconds and then placed on ice for 5 minutes. Thereafter the mixture was 
centrifuged for 30 minutes at 2500rpm.The supernatant containing the DNA was 
transferred to a NUNC tube. Two volumes of absolute ethanol were added to the solution 
to allow the DNA to precipitate out. DNA was visible as a stringy-like substance, was 
fished out using a pipette tip, and then washed in 500µl of 70% ice cold ethanol to remove 
excess salt. The DNA was air dried and resuspended in 1xTRIS-EDTA buffer. The DNA 
was stored at 4ºC. 
 2.2.2.2 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) is an in-vitro technique that catalyses DNA synthesis to 
create many identical copies of a sequence of template DNA. Primers were designed by the 
Assay Design Software of the pyrosequencer. The PCR primers were as follows: 
Forward primer: 5’TCACCAGCTTCCTCAACCACAATA 
Reverse primer which contains the tag that binds to the universal primer: 5’ 
GACGGGACACCGCTGATCGTTTAGATGATGAAATCCCCCCTCC3’) with a 
sequence specific primer (5’CACACTAAATGATTCAGGTG 3’). 
 The two PCR primers, that were complementary to the DNA sequences flanking the target 
DNA fragment, were added to the DNA template and in the presence of dNTPs buffer, 
MgCl2 and Taq polymerase; the complementary DNA sequence was synthesized. The 
enzyme responsible for this extension is DNA polymerase. The PCR cycle consists of 
denaturation of the double stranded DNA by heating the reaction to 95ºC, annealing the 
primers at a temperature specific to the primer sets and extension of the primers by the 
DNA polymerase at 72ºC.  
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Figure 2.1 Polymerase chain reaction method (Vierstraete 1999) 
2.2.2.3 Checking the PCR product 
DNA fragments can be separated, identified and purified by means of gel electrophoresis. 
This mechanism relies on the negative charge of DNA. When an electric field, 125V-
140V, is applied across the gel, the negatively charged DNA migrates through the gel 
toward the anode. The speed and distance migrated by the DNA is influenced by size of 
the DNA fragments. Using a molecular weight marker, the product can be sized accurately. 
2.2.2.4 Pyrosequencing 
Pyrosequencing is a DNA sequencing technique that is based on the detection of released 
pyrophosphate (PPi) during DNA synthesis. To 20µl of PCR product, 20µl of ddH20 was 
added. A solution of 3µl sepharose beads and 40µl binding buffer was made for each 
sample. 43µl was added to each sample. The 96 well plates were left on the shaker for 
>5mins so that the beads did not settle on the bottom of the wells.1.6µl of 10Um 
sequencing primer and 38.4µl of annealing buffer was added to each sample. The vacuum 
on the Pyrosequencer (PSQ) was applied to the 96 well plates. The vacuum device with the 
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attached beads was then moved to 70% ethanol trough for 5 seconds, then to the denaturing 
buffer for 5 seconds and then to the wash buffer for 5 seconds. The beads and purified PCR 
products were released into 96 well plates.  
The samples were then ready to be analyzed. The cascade starts with the annealing of the 
sequencing primer and a nucleic acid polymerization reaction. Upon binding of the 
nucleotide acid to its complementary base and attachment by polymerase, there is a release 
of inorganic PPi. The PPi is converted to ATP by ATP sulfurylase, which provides the 
energy to luciferase to oxidize luciferin and generate light.  
This reaction generates visible light that is proportional to the number of nucleotides 
incorporated. Because the added nucleotide is known, the sequence of the template can be 
determined. 
2.3 Statistical Methods 
Each group was tested for compliance with Hardy-Weinberg Equilibrium to assess 
potential bias in sampling or possible genotyping errors.  Once the genotypes were scored 
and allele frequencies calculated, a Chi-squared test was performed to determine if the 
difference in allele and genotype frequencies between patients and controls was 
statistically significant.  
In the Chi-squared test, the value of the test-statistic is 
 
where : Χ2 = chi-square, Oi = an observed frequency; Ei = an expected (theoretical) 
frequency, asserted by the null hypothesis 
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Chapter 3.  RESULTS  
3.1 Demographic and clinical features of RA patients 
Of the 187 RA patients 83% were females, the mean age at disease onset was 46.7 years. 
Only a minority had nodulosis and 4.8% had serious extra-articular manifestations (1 
interstitial lung disease, 1 pyoderma gangerosum, 1 vasculitis 5 scleritis). Of those tested, 
83% were RF positive and 79% were anti-CCP positive (Table 3.1).  
Table 3.1 Demographic and clinical features of the 187 Black rheumatoid arthritis patients. 
 
Variable  
Female (%) 156 (83) 
Age at disease onset in years, mean (SD)  46.7 (13.6) 
Disease duration in years, mean (SD) 10.6 (7.3) 
History of joint replacement 8/103 (7.7%) 
Swollen joint count, mean (SD) 7.9 (6.3) 
Nodulosis 14/165 (8.4%) 
Serious extra-articular manifestations 8/165 (4.8%) 
mHAQ, mean (SD) 0.87 (0.36) 
CRP at baseline, mean (SD) 34.7 (41.1) 
Anti-CCP +  72/91 (79%) 
RF + 156 (83%) 
Larsen Score mean (SD) 53.9 (34.8) 
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Patients had moderate disease activity as evidenced by the mean swollen joint count, CRP 
at baseline, history of joint replacement, mean mHAQ and Larsen scores. 
3.2 Genotype and allele frequencies 
The functional R620W SNP was nonpolymorphic in both the Black patients and controls 
(Table 3.2). The R620W was polymorphic in the White control subjects, in whom the 
frequency of the ‘T’ allele was 0.092. Figures 3.1 and 3.2 show the pyrogram differences 
between a Black patient with a C/C homozygous genotype and and White controls with a 
C/T heterozygous genotype.  
Table 3.2 Genotypes and allele frequencies in patients and control subjects 
   N Genotypes Alleles (frequency) 
C/C T/C T/T C T 
Black RA patients 187 187 0 0 374 (1.000) 0 
Black controls 93 93 0 0 186 (1.000) 0 
White controls 60 49 11 0 109 (0.908) 11 (0.092) 
N= number of subjects studied 
 
 
 
Figure 3.1 Pyrogram of a Black patient with an absent A peak and G peak only (shaded 
area), implying a C/C genotype. 
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Figure 3.2 Pyrogram of a White control subject with both A and G peaks (shaded area), 
implying a C/T genotype.  
Genotypes were in Hardy-Weinberg equilibrium for the White controls as shown below: 
 (p+q)
2
 = p
2
 + 2pq + q
2
  
p= 0.908 (C allele frequency) 
q= 0.092 (T allele frequency) 
Table 3.3 Observed and expected genotypes in White controls 
 C/C C/T T/T Total 
Observed 49 11 0 60 
Expected 49 11 0 60 
 
The chi test was calculated in the White controls.  
In the white controls the genotype was in Hardy-Weinberg equilibrium suggesting no bias 
in sampling or possible genotyping errors. The p value is not significant. The 
polymorphism was not present in the Black patients and controls; therefore statistical 
analysis was not necessary. 
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Chapter 4.  DISCUSSION 
In this study, the role of a missense SNP in a gene encoding PTPN22 was studied for its 
role in RA disease susceptibility and severity in Black South Africans. The genetic variant 
was found to be nonpolymorphic in BSA. By contrast, the White controls, which served as 
a positive control group, had a ‘T’ allele frequency very much in line with studies in other 
Caucasian populations (Plenge et al., 2005). Studies done in the Asian population showed, 
that similar to BSA, this SNP is nonpolymorphic and therefore not associated with RA.  
However, this does not mean that aberrant PTPN22 function does not play a role in RA in 
BSA with RA. Functional polymorphisms of the PTPN22, other than rs2476601, may exist 
in the BSA population. In the Japanese, PTPN22 allelic heterogeneity was studied, but 
none of the 8 other SNPs present in the European populations, were found to be 
polymorphic (Ikari et al., 2006).  
Another explanation may be that the variants in the PTPN22 gene may reflect genuine 
differences in pathogenic processes between European and BSA patients. However, this 
can only be said with certainty once all variants of the gene have been studied. This study 
shows further evidence of inter-ethnic genetic variability in RA at non-HLA loci. The 
inconsistent associations might reflect differences in sample size, although this is unlikely 
in this study as the rs2476601 was nonpolymorphic in both Black patients and controls.  
These differences might also relate to clinical phenotypic differences between populations. 
For example, Maritz et al have shown that BSA patients have relative sparing of the small 
joints of the hands (Maritz et al., 2003). 
Genotype-phenotype studies provide evidence that genetic factors modify the serological 
and clinical expression of the disease. RA is categorised into two distinct subsets, ACPA 
positive (+) and ACPA negative (-). These autoantibodies are good serological markers for 
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RA, with specificity of >95% and a sensitivity comparable to that of RF (80%) (Whiting et 
al., 2010, Hodkinson et al., 2010). The majority of the identified susceptibility genes 
confer risk to ACPA+ RA and only two genes confer risk to ACPA- RA (van der Helm-
van Mil and Huizinga, 2008). The HLA DRB1 genes associate exclusively with ACPA+ 
disease. In most studies, variants in the PTPN22 gene have also been found to be 
associated with  ACPA + however in on study the variant was associated with ACPA 
negative disease (Pierer et al., 2006). In the Asian population the PADI4 gene variant has 
not been conclusively found to be associated with ACPA status (Suzuki et al., 2006). In a 
study done in Cameroon, there was a discrepancy between the high prevalence of ACPA+ 
patients and the relative low numbers of SE positive cases. This suggests that other genes 
that have not yet been identified are associated with ACPA+ RA in African RA patients 
(Singwe-Ngandeu et al., 2010). In this study majority of patients were RF positive. ACPA 
testing in South Africa has only recently become available, thus accounting for the low 
percentage of the test done in this study population. 
Studies of genetic predictors of individual RA phenotypes have suggested association 
between PTPN22 variants and antibody status (ACPA and RF), erosive disease and age of 
onset of RA. It is associated with an earlier age of disease onset (8.6 years earlier onset in 
homozygotes of the high risk allele and 4.7 years earlier onset on heterozygotes) (Karlson 
et al., 2008).  
In this study, the prevalence of antibodies was similar to those reported in most other 
studies. The presence of ACPA in the absence of the PTPN22 high risk allele demonstrates 
the importance of ACPA in the pathogenesis of joint damage in BSAs with RA as well as 
the possibility of the role of other genetic variants not yet identified in Africans. A 
hypothesis for the disease mechanism of ACPA positive RA is as follows; citrullination 
possibly due to smoking, provokes ACPA production in individuals who have 
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susceptibility alleles of genes including HLA, followed by joint inflammation in an auto-
antibody dependant manner (Kallberg et al., 2007). 
4.1 Limitations of the study 
One of the limitations of the study is that the sample size could have been too small to 
demonstrate the polymorphism if it has a modest effect in BSA. Another limitation of the 
study is that the other variants of the gene were not studied. The smoking histories of most 
patients are unknown. The percentage of patients tested for ACPA was only 48%.  
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Chapter 5.  CONCLUSION  
The present findings are further evidence that non-HLA genetic risk is inconsistent across 
ethnic groups and that among the genetic predisposition factors for RA identified to date, 
some variants have been found to be restricted to specific ethnic groups. This might reflect 
migration history and the natural selection that shaped genetic variation in these 
populations. Additional genetic factors may also have exerted different magnitudes of risk 
for the disease among the different populations, which might be explained by their 
interactions with other genetic and environmental factors. Current evidence suggests that 
substantial heterogeneity exists in the genetics underlying autoimmunity among different 
ethnic populations. 
The findings show conclusively that the functional R620W variant, a major risk factor for 
RA in Caucasian populations, is not present and therefore does not play a role in the 
pathogenesis of RA in BSA. The verdict is still out as to whether PTPN22 has a role in RA 
susceptibility in African populations and this question could be addressed by targeted 
resequencing of PTPN22 and its flanking sequences or by quantitative mRNA studies or 
functional studies. 
5.1 The way forward  
The aim of future studies could be to resequence the PTPN22 gene in BSA individuals to 
discover additional SNPs which could then be assessed for functionality and tested in a 
case control association study. Another approach would be to carry out a comprehensive 
association study using tagging SNPs across the entire region to examine association 
within different linkage disequilibrium blocks in and around the PTPN22 gene. Potentially 
HapMap data could be used to identify suitable tag SNPs in people of African ancestry. 
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More extensive phenotyping could be done to stratify the patient group into ACPA+ and 
ACPA- RA.  
Whole genome association studies in African populations would most likely reveal 
additional susceptibility loci but would require large sample sizes. This could help explain 
differences in the clinical expression of the disease and would lead to a better 
understanding of the pathogenesis of RA and in so doing identify newer targets of therapy. 
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APPENDIX A 
AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA FOR THE 
DIAGNOSIS OF RHEUMATOID ARTHRITIS, 1987 
The diagnosis of rheumatoid arthritis requires the presence of at least four of the following 
seven features: 
1. Stiffness in and around the joint that last for 1 hour before maximal improvement 
2. Arthritis (soft tissue swelling or fluid) in three or more joint areas simultaneously 
(observed by the physician) 
3. Arthritis involving the proximal interphalangeal, metacarpophalangeal, or wrist 
joints 
4. Symmetric arthritis 
5. Rheumatoid nodules (subcutaneous, over bony prominences or extensor surfaces) 
6. Positive serum rheumatoid factor test 
7. Radiographic changes of rheumatoid arthritis (erosions, periarticular osteopenia) 
The diagnosis of rheumatoid arthritis requires that four of seven criteria be observed and 
that the first four (1 through 4) must be present for at least 6 weeks. 
 
 
29 
APPENDIX B  
 
 
 
30 
 
 
31 
APPENDIX C: ETHICS CLEARANCE CERTIFICATE  
 
 
32 
REFERENCES  
Adebajo, A. O. & Reid, D. M. (1991) The pattern of rheumatoid arthritis in West Africa 
and comparison with a cohort of British patients. Q J Med, 80, 633-40. 
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., et 
al. (1988) The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis. Arthritis Rheum, 31, 315-24. 
Baerwald, C. G., Mok, C. C., Tickly, M., Lau, C. S., Wordsworth, B. P., Ollier, B., et al. 
(2000) Corticotropin releasing hormone (CRH) promoter polymorphisms in various 
ethnic groups of patients with rheumatoid arthritis. Z Rheumatol, 59, 29-34. 
Baka, Z., Buzas, E. & Nagy, G. (2009) Rheumatoid arthritis and smoking: putting the 
pieces together. Arthritis Res Ther, 11, 238. 
Begovich, A. B., Carlton, V. E., Honigberg, L. A., Schrodi, S. J., Chokkalingam, A. P., 
Alexander, H. C., et al. (2004) A missense single-nucleotide polymorphism in a 
gene encoding a protein tyrosine phosphatase (PTPN22) is associated with 
rheumatoid arthritis. Am J Hum Genet, 75, 330-7. 
Beighton, P., Solomon, L. & Valkenburg, H. A. (1975) Rheumatoid arthritis in a rural 
South African Negro population. Ann Rheum Dis, 34, 136-41. 
Benitha, R. & Tikly, M. (2007) Functional disability and health-related quality of life in 
South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin 
Rheumatol, 26, 24-9. 
Berglin, E., Kokkonen, H., Einarsdottir, E., Agren, A. & Rantapaa Dahlqvist, S. (2010) 
Influence of female hormonal factors, in relation to autoantibodies and genetic 
markers, on the development of rheumatoid arthritis in northern Sweden: a case-
control study. Scand J Rheumatol, 39, 454-60. 
 
 
33 
Boonen, A. & Mau, W. (2009) The economic burden of disease: comparison between 
rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol, 27, S112-7. 
Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., et al. 
(2004) A functional variant of lymphoid tyrosine phosphatase is associated with 
type I diabetes. Nat Genet, 36, 337-8. 
Bowes, J. & Barton, A. (2008) Recent advances in the genetics of RA susceptibility. 
Rheumatology (Oxford), 47, 399-402. 
Burr, M. L., Naseem, H., Hinks, A., Eyre, S., Gibbons, L. J., Bowes, J., et al. (2010) 
PADI4 genotype is not associated with rheumatoid arthritis in a large UK 
Caucasian population. Ann Rheum Dis, 69, 666-70. 
Chikanza, I. C., Stein, M., Lutalo, S. & Gibson, T. (1994) The clinical, serologic and 
radiologic features of rheumatoid arthritis in ethnic black Zimbabwean and British 
Caucasian patients. J Rheumatol, 21, 2011-5. 
Cooles, F. A. & Isaacs, J. D. (2011) Pathophysiology of rheumatoid arthritis. Curr Opin 
Rheumatol, 23, 233-40. 
Cutolo, M. (2004) Estrogen metabolites: increasing evidence for their role in rheumatoid 
arthritis and systemic lupus erythematosus. J Rheumatol, 31, 419-21. 
De Vries, R. (2011) Genetics of rheumatoid arthritis: time for a change! Curr Opin 
Rheumatol, 23, 227-32. 
Dieppe, P. & Rogers, J. (1986) Art, history and the antiquity of rheumatic diseases. Clin 
Rheumatol, 5, 179-80. 
Doran, M. F., Crowson, C. S., O'fallon, W. M. & Gabriel, S. E. (2004) The effect of oral 
contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: 
a population based study. J Rheumatol, 31, 207-13. 
 
 
34 
Douglas, K. M., Pace, A. V., Treharne, G. J., Saratzis, A., Nightingale, P., Erb, N., et al. 
(2006) Excess recurrent cardiac events in rheumatoid arthritis patients with acute 
coronary syndrome. Ann Rheum Dis, 65, 348-53. 
Feitsma, A. L., Toes, R. E., Begovich, A. B., Chokkalingam, A. P., De Vries, R. R., 
Huizinga, T. W., et al. (2007) Risk of progression from undifferentiated arthritis to 
rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated 
peptide antibody positive patients. Rheumatology (Oxford), 46, 1092-5. 
Gabriel, S. E., Crowson, C. S. & O'fallon, W. M. (1999) The epidemiology of rheumatoid 
arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum, 42, 415-20. 
Gregersen, P. K. (2005) Gaining insight into PTPN22 and autoimmunity. Nat Genet, 37, 
1300-2. 
Gregersen, P. K., Silver, J. & Winchester, R. J. (1987) The shared epitope hypothesis. An 
approach to understanding the molecular genetics of susceptibility to rheumatoid 
arthritis. Arthritis Rheum, 30, 1205-13. 
Hodkinson, B., Meyer, P. W., Musenge, E., Ally, M. M., Wadee, A. A., Anderson, R., et 
al. (2010) The diagnostic utility of the anti-CCP antibody test is no better than 
rheumatoid factor in South Africans with early rheumatoid arthritis. Clin 
Rheumatol, 29, 615-8. 
Ikari, K., Momohara, S., Inoue, E., Tomatsu, T., Hara, M., Yamanaka, H., et al. (2006) 
Haplotype analysis revealed no association between the PTPN22 gene and RA in a 
Japanese population. Rheumatology (Oxford), 45, 1345-8. 
Iwamoto, T., Ikari, K., Nakamura, T., Kuwahara, M., Toyama, Y., Tomatsu, T., et al. 
(2006) Association between PADI4 and rheumatoid arthritis: a meta-analysis. 
Rheumatology (Oxford), 45, 804-7. 
 
 
35 
Johansson, M., Arlestig, L., Hallmans, G. & Rantapaa-Dahlqvist, S. (2006) PTPN22 
polymorphism and anti-cyclic citrullinated peptide antibodies in combination 
strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% 
for the disease. Arthritis Res Ther, 8, R19. 
Kallberg, H., Padyukov, L., Plenge, R. M., Ronnelid, J., Gregersen, P. K., Van Der Helm-
Van Mil, A. H., et al. (2007) Gene-gene and gene-environment interactions 
involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid 
arthritis. Am J Hum Genet, 80, 867-75. 
Karlson, E. W., Chibnik, L. B., Cui, J., Plenge, R. M., Glass, R. J., Maher, N. E., et al. 
(2008) Associations between human leukocyte antigen, PTPN22, CTLA4 
genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at 
diagnosis and erosions in a large cohort study. Ann Rheum Dis, 67, 358-63. 
Keitel, W. (2009) [The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)]. Z 
Rheumatol, 68, 851-6. 
Kelley, J. M., Hughes, L. B., Malik, A., Danila, M. I., Edberg, Y., Alarcon, G. S., et al. 
(2010) Genetic variants of STAT4 associated with rheumatoid arthritis in persons 
of Asian and European ancestry do not replicate in African Americans. Ann Rheum 
Dis, 69, 625-6. 
Kobayashi, S., Ikari, K., Kaneko, H., Kochi, Y., Yamamoto, K., Shimane, K., et al. (2008) 
Association of STAT4 with susceptibility to rheumatoid arthritis and systemic 
lupus erythematosus in the Japanese population. Arthritis Rheum, 58, 1940-6. 
Kokkonen, H., Johansson, M., Innala, L., Jidell, E. & Rantapaa-Dahlqvist, S. (2007) The 
PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide 
antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther, 
9, R56. 
 
 
36 
Kvien, T. K. (2004) Epidemiology and burden of illness of rheumatoid arthritis. 
Pharmacoeconomics, 22, 1-12. 
Kyogoku, C., Langefeld, C. D., Ortmann, W. A., Lee, A., Selby, S., Carlton, V. E., et al. 
(2004) Genetic association of the R620W polymorphism of protein tyrosine 
phosphatase PTPN22 with human SLE. Am J Hum Genet, 75, 504-7. 
Lee, H. S., Korman, B. D., Le, J. M., Kastner, D. L., Remmers, E. F., Gregersen, P. K., et 
al. (2009) Genetic risk factors for rheumatoid arthritis differ in Caucasian and 
Korean populations. Arthritis Rheum, 60, 364-71. 
Lee, H. S., Remmers, E. F., Le, J. M., Kastner, D. L., Bae, S. C. & Gregersen, P. K. (2007) 
Association of STAT4 with rheumatoid arthritis in the Korean population. Mol 
Med, 13, 455-60. 
Linn-Rasker, S. P., Van Der Helm-Van Mil, A. H., Van Gaalen, F. A., Kloppenburg, M., 
De Vries, R. R., Le Cessie, S., et al. (2006) Smoking is a risk factor for anti-CCP 
antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared 
epitope alleles. Ann Rheum Dis, 65, 366-71. 
Lubeck, D. P. (2001) A review of the direct costs of rheumatoid arthritis: managed care 
versus fee-for-service settings. Pharmacoeconomics, 19, 811-8. 
Macgregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J., Aho, K., et al. 
(2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis 
using data from twins. Arthritis Rheum, 43, 30-7. 
Mackay, K., Milicic, A., Lee, D., Tikly, M., Laval, S., Shatford, J., et al. (2003) 
Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically 
diverse populations. Rheumatology (Oxford), 42, 149-53. 
Marinou, I., Maxwell, J. R. & Wilson, A. G. (2010) Genetic influences modulating the 
radiological severity of rheumatoid arthritis. Ann Rheum Dis, 69, 476-82. 
 
 
37 
Maritz, N. G., Gerber, A. J., Greyling, S. J. & Sanda, B. B. (2003) The rheumatoid wrist in 
black South African patients. J Hand Surg Br, 28, 373-5. 
Martell, R. W., Du Toit, E. D., Kalla, A. A. & Meyers, O. L. (1989) Association of 
rheumatoid arthritis with HLA in three South African populations--whites, blacks 
and a population of mixed ancestry. S Afr Med J, 76, 189-90. 
Matesanz, F., Rueda, B., Orozco, G., Fernandez, O., Leyva, L., Alcina, A., et al. (2005) 
Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis. J 
Neurol, 252, 994-5. 
Mcinnes, I. B. & Schett, G. (2007) Cytokines in the pathogenesis of rheumatoid arthritis. 
Nat Rev Immunol, 7, 429-42. 
Meune, C., Touze, E., Trinquart, L. & Allanore, Y. (2009) Trends in cardiovascular 
mortality in patients with rheumatoid arthritis over 50 years: a systematic review 
and meta-analysis of cohort studies. Rheumatology (Oxford), 48, 1309-13. 
Meyer, P.W.A., Brighton, S.W., Anderson, R. (2004) Association of the HLA-DRB1*04 
allele and its subtype with rheumatoid arthritis in South Africa. South African 
Journal of Science, 100, 1-2 
 
Miller, S. A., Dyk, D. D. & Pelesky, H. F. (1988) A simple salting-out procedure for 
extracting DNA from human nucleated cells. Nucleic Acid Res, 16, 1215. 
Mody, G. M., Hammond, M. G. & Naidoo, P. D. (1989) HLA associations with 
rheumatoid arthritis in African blacks. J Rheumatol, 16, 1326-8. 
Mody, G. M., Shaw, J. & Ramchurren, A. (1988) Rheumatoid arthritis impact survey. S 
Afr Med J, 74, 409-10. 
Newton-Cheh, C. & Hirschhorn, J. N. (2005) Genetic association studies of complex traits: 
design and analysis issues. Mutat Res, 573, 54-69. 
Niewold, T. B.,Harrison, M., J.Paget, S. A. (2007) Anti-CCP antibody testing as a 
diagnostic and prognostic tool in rheumatoid arthritis. QJM, 4, 193-201. 
 
 
38 
Nyhall-Wahlin, B. M., Petersson, I. F., Nilsson, J. A., Jacobsson, L. T. & Turesson, C. 
(2009) High disease activity disability burden and smoking predict severe extra-
articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford), 48, 
416-20. 
Ollier, W. (2000) Rheumatoid arthritis and Epstein-Barr virus: a case of living with the 
enemy? Ann Rheum Dis, 59, 497-9. 
Orozco, G., Eyre, S., Hinks, A., Ke, X., Wilson, A. G., Bax, D. E., et al. (2010) 
Association of CD40 with rheumatoid arthritis confirmed in a large UK case-
control study. Ann Rheum Dis, 69, 813-6. 
Orozco, G., Sanchez, E., Gonzalez-Gay, M. A., Lopez-Nevot, M. A., Torres, B., Caliz, R., 
et al. (2005) Association of a functional single-nucleotide polymorphism of 
PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and 
systemic lupus erythematosus. Arthritis Rheum, 52, 219-24. 
Pattison, D. J., Symmons, D. P., Lunt, M., Welch, A., Bingham, S. A., Day, N. E., et al. 
(2005) Dietary beta-cryptoxanthin and inflammatory polyarthritis: results from a 
population-based prospective study. Am J Clin Nutr, 82, 451-5. 
Pearson, T. A. & Manolio, T. A. (2008) How to interpret a genome-wide association study. 
JAMA, 299, 1335-44. 
Pierer, M., Kaltenhauser, S., Arnold, S., Wahle, M., Baerwald, C., Hantzschel, H., et al. 
(2006) Association of PTPN22 1858 single-nucleotide polymorphism with 
rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male 
compared to female patients. Arthritis Res Ther, 8, R75. 
Pile, K. D., Tikly, M., Bell, J. I. & Wordsworth, B. P. (1992) HLA-DR antigens and 
rheumatoid arthritis in black South Africans: a study of ethnic groups. Tissue 
Antigens, 39, 138-40. 
 
 
39 
Pincus, T., Summey, J. A., Soraci, S. A., Jr., Wallston, K. A. & Hummon, N. P. (1983) 
Assessment of patient satisfaction in activities of daily living using a modified 
Stanford Health Assessment Questionnaire. Arthritis Rheum, 26, 1346-53. 
Pincus, T., Callahan, L. F., Sale, W. G., Brooks, A. L., Payne, L. E. & Vaughn, W. K. 
(1984) Severe functional declines, work disability, and increased mortality in 
seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum, 
27, 864-72. 
Plenge, R. M., Padyukov, L., Remmers, E. F., Purcell, S., Lee, A. T., Karlson, E. W., et al. 
(2005) Replication of putative candidate-gene associations with rheumatoid 
arthritis in >4,000 samples from North America and Sweden: association of 
susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet, 77, 1044-60. 
Pratt, A. G., Isaacs, J. D. & Mattey, D. L. (2009) Current concepts in the pathogenesis of 
early rheumatoid arthritis. Best Pract Res Clin Rheumatol, 23, 37-48. 
Raychaudhuri, S. (2010) Recent advances in the genetics of rheumatoid arthritis. Curr 
Opin Rheumatol, 22, 109-18. 
Saal, J. G., Krimmel, M., Steidle, M., Gerneth, F., Wagner, S., Fritz, P., et al. (1999) 
Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in 
individuals with the shared HLA-DR4 epitope. Arthritis Rheum, 42, 1485-96. 
Schneider, M., Manabile, E. & Tikly, M. (2008) Social aspects of living with rheumatoid 
arthritis: a qualitative descriptive study in Soweto, South Africa - a low resource 
context. Health Qual Life Outcomes, 6, 54. 
Seldin, M. F., Shigeta, R., Laiho, K., Li, H., Saila, H., Savolainen, A., et al. (2005) Finnish 
case-control and family studies support PTPN22 R620W polymorphism as a risk 
factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile 
idiopathic arthritis. Genes Immun, 6, 720-2. 
 
 
40 
Singwe-Ngandeu, M., Finckh, A., Bas, S., Tiercy, J. M. & Gabay, C. (2010) Diagnostic 
value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared 
epitope alleles in African rheumatoid arthritis patients. Arthritis Res Ther, 12, R36. 
Skorka, A., Bednarczuk, T., Bar-Andziak, E., Nauman, J. & Ploski, R. (2005) Lymphoid 
tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish 
population: association and gene dose-dependent correlation with age of onset. Clin 
Endocrinol (Oxf), 62, 679-82. 
Smyth, D., Cooper, J. D., Collins, J. E., Heward, J. M., Franklyn, J. A., Howson, J. M., et 
al. (2004) Replication of an association between the lymphoid tyrosine phosphatase 
locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general 
autoimmunity locus. Diabetes, 53, 3020-3. 
Solomon, L., Beighton, P., Valkenburg, H. A., Robin, G. & Soskolne, C. L. (1975) 
Rheumatic disorders in the South African Negro. Part I. Rheumatoid arthritis and 
ankylosing spondylitis. S Afr Med J, 49, 1292-6. 
Solomon, A., Christian, B. F., Dessein, P. H. & Stanwix, A. E. (2005) The need for tighter 
rheumatoid arthritis control in a South African public health care center. Semin 
Arthritis Rheum, 35, 122-31. 
Steer, S., Lad, B., Grumley, J. A., Kingsley, G. H. & Fisher, S. A. (2005) Association of 
R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid 
arthritis in a British population: evidence for an early onset/disease severity effect. 
Arthritis Rheum, 52, 358-60. 
Sugiyama, D., Nishimura, K., Tamaki, K., Tsuji, G., Nakazawa, T., Morinobu, A., et al. 
(2010) Impact of smoking as a risk factor for developing rheumatoid arthritis: a 
meta-analysis of observational studies. Ann Rheum Dis, 69, 70-81. 
 
 
41 
Suzuki, M., Miyagi, J., Kuribayashi, M., Negishi, E., Ueno, K. & Moriya, H. (2006) 
Evaluation of allele frequencies in the PADI4 gene and anti-cyclic citrullinated 
peptide antibodies of patients with rheumatoid arthritis in a Japanese population. 
Ann Rheum Dis, 65, 1399-400. 
Sverdrup, B., Kallberg, H., Bengtsson, C., Lundberg, I., Padyukov, L., Alfredsson, L., et 
al. (2005) Association between occupational exposure to mineral oil and 
rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis 
Res Ther, 7, R1296-303. 
Tikly, M., Zannettou, N. & Hopley, M. (2003) A longitudinal study of rheumatoid arthritis 
in South Africans. MedGenMed, 5, 2. 
Van Der Helm-Van Mil, A. H. & Huizinga, T. W. (2008) Advances in the genetics of 
rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis 
Res Ther, 10, 205. 
Van Der Linden, M. P., Feitsma, A. L., Le Cessie, S., Kern, M., Olsson, L. M., 
Raychaudhuri, S., et al. (2009) Association of a single-nucleotide polymorphism in 
CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum, 60, 
2242-7. 
Velaga, M. R., Wilson, V., Jennings, C. E., Owen, C. J., Herington, S., Donaldson, P. T., et 
al. (2004) The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase 
(LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab, 
89, 5862-5. 
Wesoly, J., Van Der Helm-Van Mil, A. H., Toes, R. E., Chokkalingam, A. P., Carlton, V. 
E., Begovich, A. B., et al. (2005) Association of the PTPN22 C1858T single-
nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception 
cohort. Arthritis Rheum, 52, 2948-50. 
 
 
42 
Whiting, P. F., Smidt, N., Sterne, J. A., Harbord, R., Burton, A., Burke, M., et al. (2010) 
Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing 
rheumatoid arthritis. Ann Intern Med, 152, 456-64; W155-66. 
Wick, M., Peloschek, P., Bogl, K., Graninger, W., Smolen, J. S. & Kainberger, F. (2003) 
The "X-Ray RheumaCoach" software: a novel tool for enhancing the efficacy and 
accelerating radiological quantification in rheumatoid arthritis. Ann Rheum Dis, 62, 
579-82. 
Zheng, W. & She, J. X. (2005) Genetic association between a lymphoid tyrosine 
phosphatase (PTPN22) and type 1 diabetes. Diabetes, 54, 906-8. 
 
 
 
 
 
 
 
 
 
 
